168 related articles for article (PubMed ID: 29895866)
1. Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer.
Dho SH; Kim SY; Chung C; Cho EH; Lee SY; Kim JY; Kim LK; Min SW; Lee J; Jung SH; Lim JC
Sci Rep; 2018 Jun; 8(1):8960. PubMed ID: 29895866
[TBL] [Abstract][Full Text] [Related]
2. Preclinical efficacy of hK2 targeted [
Timmermand OV; Elgqvist J; Beattie KA; Örbom A; Larsson E; Eriksson SE; Thorek DLJ; Beattie BJ; Tran TA; Ulmert D; Strand SE
Theranostics; 2019; 9(8):2129-2142. PubMed ID: 31149033
[TBL] [Abstract][Full Text] [Related]
3. Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide.
van Rij CM; Frielink C; Goldenberg DM; Sharkey RM; Lütje S; McBride WJ; Oyen WJ; Boerman OC
Cancer Biother Radiopharm; 2014 Oct; 29(8):323-9. PubMed ID: 25226447
[TBL] [Abstract][Full Text] [Related]
4. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
5. Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer.
Phaeton R; Jiang Z; Revskaya E; Fisher DR; Goldberg GL; Dadachova E
Cancer Med; 2016 Jan; 5(1):9-16. PubMed ID: 26625938
[TBL] [Abstract][Full Text] [Related]
6. Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma.
Lindenblatt D; Terraneo N; Pellegrini G; Cohrs S; Spycher PR; Vukovic D; Béhé M; Schibli R; Grünberg J
BMC Cancer; 2018 Sep; 18(1):922. PubMed ID: 30253737
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
[TBL] [Abstract][Full Text] [Related]
8. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.
Weber T; Bötticher B; Arndt MA; Mier W; Sauter M; Exner E; Keller A; Krämer S; Leotta K; Wischnjow A; Grosse-Hovest L; Strumberg D; Jäger D; Gröne HJ; Haberkorn U; Brem G; Krauss J
Cancer Lett; 2016 Oct; 381(2):296-304. PubMed ID: 27524505
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts.
Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196891
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
[TBL] [Abstract][Full Text] [Related]
12. Enhanced Theranostic Efficacy of
Chen Z; Yang Q; Song L; Qiu Y; Wang T; Wu S; Huang W; Sun X; Wang A; Kang L
Mol Pharm; 2024 May; 21(5):2544-2554. PubMed ID: 38588328
[TBL] [Abstract][Full Text] [Related]
13. L1-CAM-targeted antibody therapy and (177)Lu-radioimmunotherapy of disseminated ovarian cancer.
Fischer E; Grünberg J; Cohrs S; Hohn A; Waldner-Knogler K; Jeger S; Zimmermann K; Novak-Hofer I; Schibli R
Int J Cancer; 2012 Jun; 130(11):2715-21. PubMed ID: 21796623
[TBL] [Abstract][Full Text] [Related]
14. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
15. Combination of
Repetto-Llamazares AHV; Malenge MM; O'Shea A; Eiríksdóttir B; Stokke T; Larsen RH; Dahle J
Eur J Haematol; 2018 Oct; 101(4):522-531. PubMed ID: 29993152
[TBL] [Abstract][Full Text] [Related]
16. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
[TBL] [Abstract][Full Text] [Related]
17. 90Y-Labeled Anti-ROBO1 Monoclonal Antibody Exhibits Antitumor Activity against Small Cell Lung Cancer Xenografts.
Fujiwara K; Koyama K; Suga K; Ikemura M; Saito Y; Hino A; Iwanari H; Kusano-Arai O; Mitsui K; Kasahara H; Fukayama M; Kodama T; Hamakubo T; Momose T
PLoS One; 2015; 10(5):e0125468. PubMed ID: 26017283
[TBL] [Abstract][Full Text] [Related]
18. Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55.
Li B; Allendorf DJ; Hansen R; Marroquin J; Cramer DE; Harris CL; Yan J
Cancer Res; 2007 Aug; 67(15):7421-30. PubMed ID: 17671212
[TBL] [Abstract][Full Text] [Related]
19. Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors.
Repetto-Llamazares A; Abbas N; Bruland ØS; Dahle J; Larsen RH
Anticancer Res; 2014 Jul; 34(7):3263-9. PubMed ID: 24982330
[TBL] [Abstract][Full Text] [Related]
20. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]